Considering the variable response of the 3 GBM cell lines to nutlin-3a ND, the data indicate that detailed knowledge of a patients’ p53 pathway status is key to assessing whether nutlin-3a treatment may be of therapeutic benefit. This evidence concerns the gene TP53 and glioblastoma.